OBJECTIVE Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in Western countries and an independent risk factor for atherosclerotic heart disease. Appropriate noninvasive parameters are lacking for optimal risk stratification of cardiovascular disease in these patients. We evaluated several recently discovered noninvasive parameters for atherosclerosis in patients w...

PURPOSE OF REVIEW Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia. Nonalcoholic steatohepatitis (NASH) is a particular health concern due to the increased morbidity and mortality associated with progressive disease. At present, without specific targeted pharmac...

Research in nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), has been limited by the availability of suitable models for this disease. A number of rodent models have been described in which the relevant liver pathology develops in an appropriate metabolic context. These models are promising tools for researchers investigating one of the key issues of NASH...

AIM To understand the underlying metabolic changes in human liver disease we have applied nuclear magnetic resonance (NMR) metabolomics analysis to human liver tissue. METHODS We have carried out pilot study using 1H-NMR to derive metabolomic signatures from human liver from patients with steatosis, nonalcoholic steatohepatitis (NASH) or alcohol-related liver damage (ARLD) to identify species...

The deposition of fat in the hepatic tissue has been recognized long ago, in the early 1900s. In 1907, Hartley made the first accurate description of the fatty liver [1]. First regarded as a consequence of alcohol intake, Ludwig has observed its occurrence among non alcohol consumers in 1980, along with some of its potential harmful effects, especially the nonalcoholic steatohepatitis (NASH). S...

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after the exclusion of other causes of hepatic steatosis, including other causes of liver disease, excessive alcohol consumption, and other conditions that may lead to hepatic steatosis. NAFLD encompasses a broad clinical spectrum ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis ...

Nonalcoholic steatohepatitis (NASH) is a highly prevalent liver disease in the world. About 15% to 25% of patients with NASH may progress to cirrhosis and hepatocellular carcinoma. However, there remains no U.S. Food and Drug Administration (FDA)-approved therapy for NASH. Our previous studies indicate that the combination of leucine and metformin or leucine and icariin, a phosphodiesterase typ...

BACKGROUND & AIM Adiponectin and ghrelin are hormones that participate in hepatic lipid metabolism, and their expression in liver tissue could have important implications for nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the hepatic expression of ghrelin, adiponectin, AdipoR, and IL-6 in patients with NAFLD and normal liver. METHODS We studied patients with c...